“Octo Consulting Group (Octo), an award-winning provider of technology and modernization services to the Federal government, announced they were one of just two companies awarded an unrestricted, seven-year, $300 million BPA contract by the US Food and Drug Administration (FDA) to meet requirements outlined in the 21st Century Cure Act (H.R.34) which mandates a more streamlined and efficient drug and device approval process.
To meet this Congressional mandate, the FDA’s Center for Drug Evaluation and Research (CDER) Office of Business Informatics (OBI) has turned to Octo to support a comprehensive suite of strategic capabilities and processes, and management of an underlying data analytics technological platform that will…” Read full press release here.
Source: US Food and Drug Administration (FDA) Selects Octo for $300M Drug Resource Management System Development Contract – Business Wire, February 6, 2018.
